TMEM184A

Across TCGA pan-cancer cohorts, TMEM184A Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated TMEM184A data layer compared with 21 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher TMEM184A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TMEM184A expression acts as an unfavorable survival marker.

BLCA and PRAD are the cancer types where TMEM184A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.141	0.687	.003	21	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

TMEM184A–BLCA (OS)

Open the BLCA breakdown →